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The discovery of nitric oxide [1] generated excitement
among intensivists because, as a therapeutic gas, it
improved perfusion to ventilated lung units and
increased arterial oxygenation without obvious systemic
effects. Subsequent randomised trials in patients with
acute respiratory distress syndrome (ARDS) found short-
term improvements in oxygenation, with no effect on
mortality and an unexpected increased risk of acute kid-
ney injury (AKI) [2, 3]. In the absence of compelling bio-
logical mechanisms, one explanation could be that nitric
oxide was used harmfully in trial protocols as opposed
to clinician-directed practice. Although observational
investigations can address this hypothesis, they are
prone to bias and confounding that persist despite
efforts at statistical ‘control’ during study design or ana-
lysis. However, empirical comparisons of treatment ef-
fects in randomised trials and observational studies have
yielded mixed results [4, 5], and design alone does not
determine the truth of study findings.
Ruan and colleagues recently published a retrospective
cohort study (n = 547; 2007–2015) evaluating the rela-
tionship between inhaled nitric oxide administered in
the first 3 days of ARDS and subsequent need for renal
replacement therapy (RRT) [6]. They found that nitric
oxide was associated with a substantial increase in RRT
(adjusted hazard ratio 1.59, 95% confidence interval
1.08–2.34), consistent with meta-analyses of trials [2, 3].
The authors used propensity score matching to adjust
for confounders, a stratified analysis to evaluate clinically
important subgroups, and appropriate models to handle
the competing risk of mortality. In a sensitivity analysis,
residual confounding was evaluated using the rule-out
approach, which concluded that an unmeasured binary
confounding variable would have to be highly—and
implausibly—associated with AKI and present much
more frequently in the nitric oxide group to account for
its observed nephrotoxicity. Notwithstanding the rigour
of these analyses, we must consider their limitations.
The propensity score is the probability that a patient
will receive a treatment, conditional on baseline charac-
teristics entered into a logistic regression model with the
treatment as the dependent variable. The score is used
in several techniques to evaluate the effect of an inter-
vention. One popular approach creates a group of
patients who receive a treatment, each of whom is
matched to at least one unexposed patient with the same
propensity score. This method creates groups that
appear to be well-balanced in a table of baseline charac-
teristics. Unlike multivariable regression, propensity
score-matched cohorts mimic the familiar structure of a
randomised trial. Outcomes are compared directly be-
tween groups, preferably accounting for the matched
nature of the data. However, propensity scoring does not
overcome a fundamental limitation of observational
studies: only measured confounders can be assessed. In
addition, the ‘rule-out’ simulations to determine the
necessary magnitude of a hypothetical confounder that
would render the exposure harmless does not consider
the more plausible scenario of several unmeasured
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confounders, each moderately associated with the out-
come of AKI and more prevalent in the nitric oxide group.
For example, it is possible that physicians who prescribed
inhaled nitric oxide in the first 3 days of ARDS also pre-
ferred other more aggressive interventions, such as
broader antimicrobials with more toxic side effects, or
more frequent imaging with contrast media.
Another threat to study validity is that patients given
nitric oxide may have had a worsening overall clinical
trajectory prior to initiation, which cannot be modelled
using baseline characteristics alone. If so, then patients
who received nitric oxide may simply have been sicker,
despite the similarity in propensity score, and thus more
likely to receive RRT. Finally, concordant analyses of
related outcomes, such as stage 3 AKI (which includes
creatinine- and urine output-based criteria) and progres-
sion of AKI stage, would have reassured readers that the
increased risk of RRT was not simply due to earlier
physician initiation in these patients.
If we accept the finding that nitric oxide harms the kid-
ney, what are the mechanisms? One reliable effect of nitric
oxide is a short-term improvement in oxygenation. Recent
studies have highlighted the increased mortality and organ
failure associated with moderate and extreme arterial
hyperoxia [7, 8], although the kidney may be spared [8].
Alternatively, or in addition, reactive nitrogen species
formed as a product of nitric oxide and high fractional
oxygen concentration delivery in ARDS may create a pro-
inflammatory response leading to renal vasoconstriction
and injury [3]. Given that these mechanisms are largely
speculative, measurements of both nitric oxide metabo-
lites and renal biomarkers in animals or patients with
ARDS who receive this treatment are required to further
elucidate the pathophysiology of AKI.
Like investigators using statistical tools to control con-
founding in observational datasets, intensivists have
sought to control and correct physiologic abnormalities
to improve patient outcomes. However, recent evidence
in critical care has refuted the notion that normalized
physiology benefits patients; examples include the sur-
vival advantage with lower hemoglobin, lower intensity
ventilation, and higher blood sugar [9–11]. Similarly,
interventions designed to moderate the intensity of
ventilation to reduce ventilator-associated lung injury,
such as prone positioning, pressure- and volume-limited
ventilation strategies, and possibly extracorporeal sup-
port, have had greater impact on patient survival [9, 12,
13]. Given these findings, short-term physiological im-
provements are insufficient to justify an intervention in
critically ill patients.
Health services researchers must settle for incomplete
statistical control despite innovative and rigorous
methods, while clinicians aim for physiologic under-
standing and sufficient rather than complete correction
of abnormal parameters. Although the rule of rescue will
likely mandate consideration of nitric oxide for patients
with perceived life-threatening hypoxemia, the lack of
survival benefit even in this dire setting [14] and in-
creased risk of RRT should encourage transient use
while more effective strategies are implemented. Since
death from refractory hypoxemia in patients with ARDS
is uncommon and nitric oxide is expensive, the
resource-intensive side effect of RRT may simply
reinforce efforts to curtail utilisation. Because additional
trials of nitric oxide for ARDS are highly unlikely, future
research on its renal effects should focus on mechanisms
of AKI. In addition, a ‘big data’ approach would harness
electronic patient record databases to explore whether
temporal and hospital-level variation in nitric oxide util-
isation for patients with ARDS is associated with AKI.
Abbreviations
AKI: Acute kidney injury; ARDS: Acute respiratory distress syndrome;





Availability of data and materials
Not applicable.
Authors’ contributions
LM wrote the first draft of the manuscript. LM and NKJA revised the
manuscript. Both authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethical approval and consent to participate
Not applicable.
Author details
1Interdepartmental Division of Critical Care, Sinai Health System, University of
Toronto, Toronto, ON, Canada. 2Department of Critical Care Medicine and
Interdepartmental Division of Critical Care, Sunnybrook Health Sciences
Centre and University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N
3M5, Canada.
References
1. Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The
discovery of endothelium-derived relaxing factor and its importance in the
identification of nitric oxide. JAMA. 1996;276(14):1186–8.
2. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect
of nitric oxide on oxygenation and mortality in acute lung injury: systematic
review and meta-analysis. BMJ. 2007;334(7597):779.
3. Ruan SY, Huang TM, Wu HY, Wu HD, Yu CJ, Lai MS. Inhaled nitric oxide
therapy and risk of renal dysfunction: a systematic review and meta-analysis
of randomized trials. Crit Care. 2015;19:137.
4. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with
observational study designs compared with those assessed in randomized
trials. Cochrane Database Syst Rev. 2014;4:MR000034.
Munshi and Adhikari Critical Care  (2017) 21:83 Page 2 of 3
5. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of
treatment effects for mortality from routinely collected data and
subsequent randomized trials: meta-epidemiological survey. BMJ.
2016;352:i493.
6. Ruan SY, Wu HY, Lin HH, Wu HD, Yu CJ, Lai MS. Inhaled nitric oxide and the
risk of renal dysfunction in patients with acute respiratory distress
syndrome: a propensity-matched cohort study. Crit Care. 2016;20(1):389.
7. Helmerhorst HJ, Arts DL, Schultz MJ, van der Voort PH, Abu-Hanna A, de
Jonge E, van Westerloo DJ. Metrics of arterial hyperoxia and associated
outcomes in critical care. Crit Care Med. 2017;45(2):187–95.
8. Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, Morelli A,
Antonelli M, Singer M. Effect of conservative vs conventional oxygen
therapy on mortality among patients in an intensive care unit: the Oxygen-
ICU Randomized Clinical Trial. JAMA. 2016;316(15):1583–9.
9. The Acute Respiratory Distress Syndrome Network. Ventilation with lower
tidal volumes as compared with traditional tidal volumes for acute lung
injury and the acute respiratory distress syndrome. N Engl J Med.
2000;342(18):1301–8.
10. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster
D, Dhingra V, Bellomo R, Cook D, Dodek P, et al. Intensive versus
conventional glucose control in critically ill patients. N Engl J Med.
2009;360(13):1283–97.
11. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber
S, Arnal JM, Perez D, Seghboyan JM, et al. Neuromuscular blockers in early
acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–16.
12. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E,
Badet M, Mercat A, Baudin O, et al. Prone positioning in severe acute
respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–68.
13. Bein T, Weber-Carstens S, Goldmann A, Muller T, Staudinger T, Brederlau J,
Muellenbach R, Dembinski R, Graf BM, Wewalka M, et al. Lower tidal volume
strategy (approximately 3 ml/kg) combined with extracorporeal CO2
removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe
ARDS: the prospective randomized Xtravent-study. Intensive Care Med.
2013;39(5):847–56.
14. Adhikari NK, Dellinger RP, Lundin S, Payen D, Vallet B, Gerlach H, Park KJ, Mehta
S, Slutsky AS, Friedrich JO. Inhaled nitric oxide does not reduce mortality in
patients with acute respiratory distress syndrome regardless of severity:
systematic review and meta-analysis. Crit Care Med. 2014;42(2):404–12.
Munshi and Adhikari Critical Care  (2017) 21:83 Page 3 of 3
